Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Mouse (Murine) ASXL1 Antibodies:
anti-Human ASXL1 Antibodies:
anti-Rat (Rattus) ASXL1 Antibodies:
Go to our pre-filtered search.
Human Polyclonal ASXL1 Primary Antibody for IHC - ABIN965603
Fisher, Berger, Randazzo, Brock: A human homolog of Additional sex combs, ADDITIONAL SEX COMBS-LIKE 1, maps to chromosome 20q11. in Gene 2003
Human Monoclonal ASXL1 Primary Antibody for ELISA, WB - ABIN949894
Davies, Yip, Fernandez-Mercado, Woll, Agirre, Prosper, Jacobsen, Wainscoat, Pellagatti, Boultwood: Silencing of ASXL1 impairs the granulomonocytic lineage potential of human CD34? progenitor cells. in British journal of haematology 2013
This study proposed the first Asxl1 mutation knock-in mouse model and showed mutated Asxl1 lowered the threshold of MN1-driven engraftment and exhibited distinct biological functions on physiological and malignant hematopoiesis, although it was insufficient to lead to blood malignancies.
Loss of Asxl1 alters self-renewal and cell fate of bone marrow stromal cell, leading to Bohring-Opitz-like syndrome in mice.
implicate Asxl1 in the maintenance of podocyte structure via its association with Wtip (show WTIP Antibodies) and in the regulation of WT1 (show WT1 Antibodies) signaling during early kidney development
ASXL1 truncation mutations confer gain-of-function on the ASXL-BAP1 (show BAP1 Antibodies) complex.
Asxl1-/- fetuses have reduced body weight and display cleft palate, anophthalmia as well as ventricular septal defects and a failure in lung maturation.
Asxl1 functions as a tumor suppressor to maintain hematopoietic cell homeostasis
C-terminal-truncating Asxl1 mutations inhibited myeloid differentiation and induced myelodysplastic syndrome-like disease
Constitutive loss of Asxl1 results in developmental abnormalities, including anophthalmia, microcephaly, cleft palate, and mandibular malformations. Hematopoietic-specific deletion results in cytopenia and dysplasia with increased hematopoietic stem cells
ASXL1 represses, whereas ASXL2 (show ASXL2 Antibodies) increases, the expression of adipogenic genes, most of which are PPARgamma (show PPARG Antibodies) targets
Asxl1 is needed for normal hematopoiesis.
Data indicate that additional Sex Comb-Like 1 protein (ASXL1)-mut (show MUT Antibodies) were associated with poor prognosis in de novo AML (show RUNX1 Antibodies) with trisomy 8 as the sole aberration.
our data further validate the prognostic role of ASXL1 mutations in chronic myelomonocytic leukemia
The authors demonstrate that BAP1 (show RNF2 Antibodies) deubiquitinase activity and its association with ASXL1 to form the Polycomb (show CBX2 Antibodies) repressive deubiquitinase complex (PR-DUB) impacts TRAIL sensitivity implicating transcriptional modulation as an underlying mechanism.
Prognostic interaction between bone marrow morphology and SF3B1 (show SF3B2 Antibodies) and ASXL1 mutations in myelodysplastic syndromes with ring sideroblasts
EZH2 (show EZH2 Antibodies) mutations in chronic myelomonocytic leukemia cluster with ASXL1 mutations and their co-occurrence is prognostically detrimental.
Transcriptome analysis revealed that ASXL1 mutations altered differentiation of U937 cells by disturbing genes involved in myeloid differentiation.
This study identifies the unique role of JAG1 (show JAG1 Antibodies)-induced Notch (show NOTCH1 Antibodies) activation in the pathogenesis of multiple myeloma. This is of significant clinical relevance due to the prevalence of truncating ASXL1 mutations and their effect on clinical outcome in patients with myeloid malignancies
Evidence of a key role for ASXL1 in erythropoiesis, ASXL1 loss hinders erythroid development/maturation.
Patients harbouring ASXL1 and/or CBL (show CBL Antibodies) mutations (n = 8, 8 deaths, median OS = 11 months) had a significantly worse OS as compared to those without either mutation (n = 11, 4 deaths, median OS = 84 months) (P = 0.0002) (Fig 1a).
Patients with mutations 6 showed higher rate of achieving major molecular response than those<6 (P=0.0381). Mutations in epigenetic regulator, ASXL1, TET2 (show TET2 Antibodies), TET3 (show TET3 Antibodies), KDM1A (show KDM1A Antibodies) and MSH6 (show MSH6 Antibodies) were found in 25% of patients. TET2 (show TET2 Antibodies) or TET3 (show TET3 Antibodies), AKT1 (show AKT1 Antibodies) and RUNX1 (show RUNX1 Antibodies) were mutated in one patient each. ASXL1 was mutated within exon 12 in three cases
This gene is similar to the Drosophila additional sex combs gene, which encodes a chromatin-binding protein required for normal determination of segment identity in the developing embryo. The protein is a member of the Polycomb group of proteins, which are necessary for the maintenance of stable repression of homeotic and other loci. The protein is thought to disrupt chromatin in localized areas, enhancing transcription of certain genes while repressing the transcription of other genes. The protein encoded by this gene functions as a ligand-dependent co-activator for retinoic acid receptor in cooperation with nuclear receptor coactivator 1. Mutations in this gene are associated with myelodysplastic syndromes and chronic myelomonocytic leukemia. Alternative splicing results in multiple transcript variants.
additional sex combs like 1
, additional sex combs-like protein 1
, putative Polycomb group protein ASXL1